Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

21

Revenue 2017

Biogen Idec

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Biogen Idec's 2013 Oncology and CNS sales performance.

Biogen Idec Inc.

J&J’s MS drug ponesimod receives approval in the US

J&J’s MS drug ponesimod receives approval in the US

As well as the newer therapies, a range of blockbuster drugs are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA NICE currently recommends Biogen’s Spinraza (nusinersen) for certain patients with pre-symptomatic SMA and SMA types 1, 2 or 3 as part of a managed access agreement.

ICER extends evaluation of Biogen’s aducanumab after FDA delay

ICER extends evaluation of Biogen’s aducanumab after FDA delay The FDA considered the additional information a ‘major amendment’ to Biogen’s application, hence the need for the additional time for review. ... It is unclear what additional data Biogen submitted to the FDA after the agency’s request for

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes Another amyloid-targeting treatment, Biogen’s aducanumab, is currently being reviewed by the US Food and Drug Administration (FDA).

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma Biogen has treated the first patient in a phase 4 study evaluating its spinal muscular atrophy (SMA) treatment Spinraza in infants and children who have ‘unmet clinical needs’ after previously receiving ... Despite launching as a one-time treatment

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics